Marco Boorsma PhD
General Partner
Developing fast-acting intranasal drugs to resolve cardiac rhythm disorders
Milestone Pharmaceutical develops novel small molecule therapeutics for transient cardiovascular conditions.
The company’s lead product, etripamil (MSP-2017) is a potent, short-acting nasally-delivered calcium channel antagonist in phase 3 development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).
Human Health
CA
1111 Dr.-Frederik-Philips Boulevard
Suite 420
Saint-Laurent, (Quebec)
H4M 2X6
Canada
Industry
Biotech
Status
Past
Location
Canada
Forbion team